Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Metabolic Medicine

Long-Term Surveillance: Protecting Eyes, Nerves, and Heart

At a Glance

Managing MTP deficiency long-term requires proactive monitoring of the eyes, nerves, and heart. Regular specialist exams can catch complications like retinopathy, neuropathy, and cardiomyopathy early, helping preserve health and prevent severe symptoms.

While the initial focus of MTP deficiency is often on preventing acute metabolic crises, the long-term journey involves proactive surveillance. Even with excellent dietary management, some patients may develop complications in the eyes, nerves, and heart [1]. By understanding these risks, you can work with your care team to catch changes early and adjust treatment as needed [2].

Protecting the Vision: Pigmentary Retinopathy

One of the most specific long-term concerns in MTP deficiency—particularly the LCHAD subtype—is pigmentary retinopathy [3]. This is a progressive change in the retina, the light-sensitive layer at the back of the eye.

  • Why it happens: The exact cause is still being studied, but it is believed that the buildup of toxic fatty acid intermediates damages the retinal cells over time [4][5].
  • What to watch for: Early signs can be subtle, such as difficulty seeing in the dark (night blindness) or a gradual loss of peripheral (side) vision [6][7].
  • Monitoring: Regular exams with a specialized ophthalmologist are essential, typically starting in early childhood and occurring annually. Tests like Optical Coherence Tomography (OCT)—which takes detailed pictures of the retinal layers—or an Electroretinogram (ERG) help track the health of the eye [6][8]. While diet alone may not stop retinopathy, early detection helps preserve as much vision as possible [9].

Safeguarding the Nerves: Peripheral Neuropathy

Over time, some patients develop peripheral neuropathy, which is damage to the nerves that carry messages between the brain and the rest of the body [10].

  • Symptoms: This often presents as a “pins and needles” sensation, numbness, or weakness in the hands and feet [11][12]. In children, it might look like frequent tripping or a change in their walking pattern [10].
  • Progressive Nature: This is typically a “slowly progressive” condition [10]. It may mimic other nerve disorders, so it is vital that a neurologist familiar with metabolic diseases performs regular evaluations.
  • Tracking Health: Doctors may use Nerve Conduction Studies (NCS) or specialized imaging like Magnetic Resonance Neurography (MRN) to look for subclinical nerve changes before they cause major symptoms [13].

Heart Health: Monitoring Cardiomyopathy

The heart is a high-energy organ that normally relies heavily on fat for fuel. In MTP deficiency, the heart is at risk for cardiomyopathy (weakening of the heart muscle) and arrhythmias (irregular heartbeats) [5][14].

  • Cardiac Surveillance: Even if the heart was healthy at birth, long-term follow-up is necessary. This usually involves regular echocardiograms (ultrasounds of the heart) and EKGs to ensure the heart muscle remains strong and the rhythm is stable [15][2].
  • Prevention through Fuel: Maintaining a steady supply of energy through diet and supplements (like MCT oil or Triheptanoin) is the best way to support heart function [15][16].

Managing Muscle Health and Exercise

For many, especially those with “late-onset” or milder forms, the primary long-term challenge is rhabdomyolysis (rapid muscle breakdown) and exercise intolerance [17][18].

  • Activity Planning: Exercise is healthy, but it must be managed carefully. Patients should avoid high-intensity or prolonged exertion without proper “fueling” (extra carbohydrates or MCT oil) before and during the activity [19][15].
  • Warning Signs: Severe muscle pain, weakness, or “cola-colored” urine (myoglobinuria) are signs of muscle breakdown and require immediate medical attention to protect the kidneys [18][20].

A Roadmap for Proactive Care

Think of long-term management as a partnership. By attending regular check-ups with your “surveillance team”—the metabolic specialist, ophthalmologist, neurologist, and cardiologist—you are creating a safety net that supports a full and active life [2][21].

Common questions in this guide

How often should someone with MTP deficiency get an eye exam?
Regular eye exams should typically start in early childhood and occur annually. Tests like an Optical Coherence Tomography (OCT) or Electroretinogram (ERG) help track the health of the retina to catch pigmentary retinopathy early.
What are the early signs of nerve damage in MTP deficiency?
Early signs of peripheral neuropathy can include a pins and needles sensation, numbness, or weakness in the hands and feet. In children, this may appear as frequent tripping, clumsiness, or a change in how they walk.
How is heart health monitored in MTP deficiency?
Doctors monitor heart health using regular echocardiograms and EKGs to ensure the heart muscle remains strong and the rhythm is stable. Maintaining a steady energy supply through diet and supplements also supports long-term heart function.
How can I prevent muscle breakdown during exercise with MTP deficiency?
To prevent rapid muscle breakdown, avoid high-intensity or prolonged exertion without proper fueling. Consuming extra carbohydrates or MCT oil before and during activity provides the necessary energy to protect your muscles.
What are the warning signs of muscle breakdown after exercise?
Severe muscle pain, weakness, or dark, cola-colored urine are warning signs of muscle breakdown known as rhabdomyolysis. If these occur, you should seek immediate medical attention to protect your kidneys.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How often should I or my child have a specialized eye exam (like an OCT or ERG) to screen for pigmentary retinopathy?
  2. 2.What are the early signs of peripheral neuropathy we should look for at home, such as changes in walking or tingling in the hands and feet?
  3. 3.Is heart muscle function currently stable, and how frequently do we need a follow-up echocardiogram?
  4. 4.If I or my child develop muscle pain or weakness after exercise, what are the immediate steps I should take to prevent rhabdomyolysis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    A Focus on the Role of Dietary Treatment in the Prevention of Retinal Dysfunction in Patients with Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency: A Systematic Review.

    Maines E, Gugelmo G, Vitturi N, et al.

    Children (Basel, Switzerland) 2025; (12(3)) doi:10.3390/children12030374.

    PMID: 40150656
  2. 2

    Long-term monitoring of fatty acid oxidation defects: results from a MetabERN survey.

    Schwantje M, Grünert SC, Fuchs SA

    Orphanet journal of rare diseases 2024; (19(1)):21 doi:10.1186/s13023-024-03024-0.

    PMID: 38245779
  3. 3

    Ophthalmic Symptoms of Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency: A Report of Three Cases.

    Lange N, Bodetko AM, Mozrzymas R, Kowal-Lange A

    Case reports in ophthalmology 2024; (15(1)):310-319 doi:10.1159/000537895.

    PMID: 38595698
  4. 4

    Characterization of the Pank2-/- mouse retinal phenotype as a pre-clinical model for pantothenate kinase-associated neurodegeneration.

    Su GL, Jeong SY, Wafai D, et al.

    PloS one 2025; (20(6)):e0326866 doi:10.1371/journal.pone.0326866.

    PMID: 40554626
  5. 5

    Deregulation of mitochondrial functions provoked by long-chain fatty acid accumulating in long-chain 3-hydroxyacyl-CoA dehydrogenase and mitochondrial permeability transition deficiencies in rat heart--mitochondrial permeability transition pore opening as a potential contributing pathomechanism of cardiac alterations in these disorders.

    Cecatto C, Hickmann FH, Rodrigues MD, et al.

    The FEBS journal 2015; (282(24)):4714-26 doi:10.1111/febs.13526.

    PMID: 26408230
  6. 6

    A proposal for an updated staging system for LCHADD retinopathy.

    Wongchaisuwat N, Gillingham MB, Yang P, et al.

    Ophthalmic genetics 2024; (45(2)):140-146 doi:10.1080/13816810.2024.2303682.

    PMID: 38288966
  7. 7

    Identification and functional characterization of mutations within HADHB associated with mitochondrial trifunctional protein deficiency.

    Liu ZR, Dong HL, Ma Y, Wu ZY

    Mitochondrion 2019; (49()):200-205 doi:10.1016/j.mito.2019.09.004.

    PMID: 31521624
  8. 8

    Retinitis pigmentosa as a clinical presentation of LCHAD deficiency: A clinical case and review of the literature.

    García García LC, Zamorano Martín F, Rocha de Lossada C, et al.

    Archivos de la Sociedad Espanola de Oftalmologia 2021; (96(9)):496-499 doi:10.1016/j.oftale.2020.07.013.

    PMID: 34479707
  9. 9

    Retained visual function in a subset of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD).

    Dulz S, Atiskova Y, Engel P, et al.

    Ophthalmic genetics 2021; (42(1)):23-27 doi:10.1080/13816810.2020.1836658.

    PMID: 33107778
  10. 10

    Early-Onset Sensorimotor Axonal Neuropathy as Sole Manifestation of HADHA-Related Disorder/ Mitochondrial Trifunctional Protein Defect.

    Balletto G, Barbagallo G, Cataldi M, et al.

    Journal of child neurology 2026; (41(2)):252-258 doi:10.1177/08830738251356850.

    PMID: 40820380
  11. 11

    Sensory neuronopathy as a major clinical feature of mitochondrial trifunctional protein deficiency in adults.

    Nadjar Y, Souvannanorath S, Maisonobe T, et al.

    Revue neurologique 2020; (176(5)):380-386 doi:10.1016/j.neurol.2019.11.011.

    PMID: 32253025
  12. 12

    Peripheral Neuropathy in Mitochondrial Trifunctional Protein Deficiency due to a Variant in HADHA Gene.

    Abedidoust S, Badv RS, Saliani A, Azari-Yam A

    Iranian journal of pathology 2024; (19(3)):355-358 doi:10.30699/IJP.2024.2010490.3163.

    PMID: 39687448
  13. 13

    MR Neurography in Children and Adolescents: Multiparametric Assessment of Peripheral Nerve Involvement in Long-chain Fatty Acid Oxidation Disorders.

    Preisner F, Garbade SF, Grünert SC, et al.

    Investigative radiology 2026; doi:10.1097/RLI.0000000000001274.

    PMID: 41626767
  14. 14

    Mitochondrial Trifunctional Protein Deficiency: Severe Cardiomyopathy and Cardiac Transplantation.

    Bursle C, Weintraub R, Ward C, et al.

    JIMD reports 2018; (40()):91-95 doi:10.1007/8904_2017_68.

    PMID: 29124685
  15. 15

    Inborn Errors of Metabolism with Myopathy: Defects of Fatty Acid Oxidation and the Carnitine Shuttle System.

    El-Gharbawy A, Vockley J

    Pediatric clinics of North America 2018; (65(2)):317-335 doi:10.1016/j.pcl.2017.11.006.

    PMID: 29502916
  16. 16

    Electrophysiological Abnormalities in VLCAD Deficient hiPSC-Cardiomyocytes Do not Improve with Carnitine Supplementation.

    Verkerk AO, Knottnerus SJG, Portero V, et al.

    Frontiers in pharmacology 2020; (11()):616834 doi:10.3389/fphar.2020.616834.

    PMID: 33597881
  17. 17

    Aspirin increases mitochondrial fatty acid oxidation.

    Uppala R, Dudiak B, Beck ME, et al.

    Biochemical and biophysical research communications 2017; (482(2)):346-351 doi:10.1016/j.bbrc.2016.11.066.

    PMID: 27856258
  18. 18

    Novel mutations in the HADHB gene causing a mild phenotype of mitochondrial trifunctional protein (MTP) deficiency.

    Ørstavik K, Arntzen KA, Mathisen P, et al.

    JIMD reports 2022; (63(3)):193-198 doi:10.1002/jmd2.12276.

    PMID: 35433169
  19. 19

    Nutritional Management of Patients with Fatty Acid Oxidation Disorders.

    Peña-Quintana L, Correcher-Medina P

    Nutrients 2024; (16(16)) doi:10.3390/nu16162707.

    PMID: 39203843
  20. 20

    Mitochondrial trifunctional protein deficiency as a polyneuropathy etiology in childhood.

    Uzun ÖÜ, Çavdarlı B, Karalök S

    The Turkish journal of pediatrics 2021; (63(6)):1097-1102.

    PMID: 35023662
  21. 21

    Qualitative evaluation of the symptoms and quality of life impacts of long-chain fatty acid oxidation disorders.

    Williams-Hall R, Tinsley K, Kruger E, et al.

    Therapeutic advances in endocrinology and metabolism 2022; (13()):20420188211065655 doi:10.1177/20420188211065655.

    PMID: 35035873

This page is for informational purposes only and does not replace professional medical advice. Always consult your metabolic specialist and care team regarding long-term surveillance for MTP deficiency.

Get notified when new evidence is published on Mitochondrial trifunctional protein deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.